merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for other treatments</answer>
<question_number>3</question_number>
<answer>No correlation</answer>
<question_number>4</question_number>
<answer>It may raise concerns about Kisunla's safety</answer>
<question_number>5</answer>
<answer>The expectation that patients can stop Kisunla after plaques are cleared</answer>
<question_number>6</answer>
<answer>It might discourage patients from participating in other clinical trials</answer>
<question_number>7</answer>
<answer>Patients can stop the drug after it clears the protein, reducing the overall cost and inconvenience</answer>
<question_number>8</answer>
<answer>Amyloid</answer>
<question_number>9</answer>
<answer>Dr. Michael Greicius</answer>
<question_number>10</answer>
<answer>Intermediate tau levels</answer>